Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEUPROLIDE ACETATE

All injection strengths: general benefit

Other products in the same Health Canada class (L02A, L02AE) — coverage varies; not interchangeable

  • Buserelin (Suprefact Depot 2 Months): general benefit
  • Goserelin (Zoladex): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, Not a benefit

Lupron Depot PDS · DIN 02239834 · 11.25mg · injection-Kit

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 02239834 Manufacturer: Abbott Laboratories Limited; listing date 2000-07-17 Health Canada: Marketed since 2013-11-04 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 11.25 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $1205.8956/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1205.8956 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63321 · Verify on the e-Formulary ↗ (DIN 02239834)

Source record
DIN 02239834: Lupron Depot PDS Raw flags: sec3=Y Item: 100000148; group id 170; item number 0289; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 11.25mg Recorded listing: General benefit Source prices (unrounded): $1205.8956; ministry $1205.8956 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239834 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63321
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

GOSERELIN ACETATE

· 2 products · General benefit · strengths: 3.6mg, 10.8mg · Depot Inj

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endometriosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: GOSERELIN ACETATE GOSERELIN ACETATE · General benefit COPYRIGHT 2017 TERSERA THERAPEUTICS LLC Page 3 of 45 Benign Conditions  ZOLADEX is indicated for the hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. PM: https://pdf.hres.ca/dpd_pm/00042728.PDF; date December 21, 2017; DIN 02049325; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) must be administered by a healthcare professional. Central Precocious Puberty (CPP) LUPRON DEPOT 3.75 mg (1-Month) and 7.5 mg (1-Month) are indicated for: • the treatment of children with central precocious puberty (CPP). Children should be selected using the following criteria: 1. Clinical diagnosis of CPP (idiopathic or neurogenic) with onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males. 2. Clinical diagnosis should be confirmed prior to initiation of therapy as follows: a) Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone (GnRH) stimulation test. The sensitivity and methodology of this assay must be understood. b) Bone age advanced one year beyond the chronological age. 3. Baseline evaluation should also include: a) Height and weight measurements b) Sex steroid levels c) Adrenal steroid level to exclude congenital adrenal hyperplasia d) Beta human chorionic gonadotropin level to rule out a chorionic gonadotropin s… https://pdf.hres.ca/dpd_pm/00082398.PDF PM date: 2025-11-13 Source product: LUPRON DEPOT; DIN 00836273; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.